DEVELOPMENT SITE ONLY
Please use current guidelines available on the UHNM intranet for patient treatment
Please use current guidelines available on the UHNM intranet for patient treatment
Be alert: Sodium nitroprusside is a very potent agent
INDICATIONS
- Accelerated hypertension
- Sodium nitroprusside is a very potent agent
- use only on the advice of a renal SpR/consultant
- use only on wards (e.g. critical care unit/CCU) where continuous monitoring of BP (preferably via arterial line) is possible
CONTRA-INDICATIONS
- Compensatory hypertension
- Impaired cerebral circulation
- Leber’s optic atrophy
- Severe B12 deficiency
PREPARATIONS
- Sodium nitroprusside 50 mg ampoules/vials for reconstitution
DILUENTS
- Glucose 5%
ADMINISTRATION
- Administer sodium nitroprusside either in a 50 mL syringe via a syringe pump, or in 500 mL bags using a controlled infusion device for precise control of flow rate
- choice of bag size or use of syringe pump depend on dosage, patient weight and fluid status and availability of equipment
- Take care to avoid extravasation. Check infusion site regularly
How to start and adjust doses
- Initially 0.3 microgram/kg/min by IV infusion
- increase to 0.5 microgram/kg/min
- then in increments of 0.5 microgram/kg/min according to response allowing 5-10 min between each increment
- Maximum dose = 8 microgram/kg/min
Infusion via syringe pump
- Reconstitute sodium nitroprusside with 2 mL of glucose 5%
- Withdraw resulting solution and make up to 50 mL with glucose 5% (50 mg in 50 mL = 1 mg/mL)
- mix thoroughly
- Infusion solution has a faint orange-brownish tint. If it is highly coloured do not use
- Sodium nitroprusside must be protected from light
- immediately wrap syringe and tubing with foil provided
- infusion solution is then stable for up to 24 hr from time of preparation
Table 1: Administration of sodium nitroprusside (1 mg/mL) via syringe pump (rate mL/hr)
Concentration = 50 mg in 50 mL = 1000 microgram/mL (1 mg/mL). If weight <45 kg or >100 kg, discuss with renal team
Dosage (microgram/ kg/min) |
Weight (kg) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
45 | 50 | 55 | 60 | 65 | 70 | 75 | 80 | 85 | 90 | 95 | 100 | |
0.3 | 0.8 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.4 | 1.4 | 1.5 | 1.6 | 1.7 | 1.8 |
0.5 | 1.4 | 1.5 | 1.7 | 1.8 | 2.0 | 2.1 | 2.3 | 2.4 | 2.6 | 2.7 | 2.9 | 3.0 |
1.0 | 2.7 | 3.0 | 3.3 | 3.6 | 3.9 | 4.2 | 4.5 | 4.8 | 5.1 | 5.4 | 5.7 | 6.0 |
1.5 | 4.1 | 4.5 | 5.0 | 5.4 | 5.9 | 6.3 | 6.8 | 7.2 | 7.7 | 8.1 | 8.6 | 9.0 |
2.0 | 5.4 | 6.0 | 6.6 | 7.2 | 7.8 | 8.4 | 9.0 | 9.6 | 10.2 | 10.8 | 11.4 | 12.0 |
2.5 | 6.8 | 7.5 | 8.3 | 9.0 | 9.8 | 10.5 | 11.3 | 12.0 | 12.8 | 13.5 | 14.3 | 15.0 |
3.0 | 8.1 | 9.0 | 9.9 | 10.8 | 11.7 | 12.6 | 13.5 | 14.4 | 15.3 | 16.2 | 17.1 | 18.0 |
3.5 | 9.5 | 10.5 | 11.6 | 12.6 | 13.7 | 14.7 | 15.8 | 16.8 | 17.9 | 18.9 | 20.0 | 21.0 |
4.0 | 10.8 | 12.0 | 13.2 | 14.4 | 15.6 | 16.8 | 18.0 | 19.2 | 20.4 | 21.6 | 22.8 | 24.0 |
4.5 | 12.2 | 13.5 | 14.9 | 16.2 | 17.6 | 18.9 | 20.3 | 21.6 | 23.0 | 24.3 | 25.7 | 27.0 |
5.0 | 13.5 | 15.0 | 16.5 | 18.0 | 19.5 | 21.0 | 22.5 | 24.0 | 25.5 | 27.0 | 28.5 | 30.0 |
5.5 | 14.9 | 16.5 | 18.2 | 19.8 | 21.5 | 23.1 | 24.8 | 26.4 | 28.1 | 29.7 | 31.4 | 33.0 |
6.0 | 16.2 | 18.0 | 19.8 | 21.6 | 23.4 | 25.2 | 27.0 | 28.8 | 30.6 | 32.4 | 34.2 | 36.0 |
6.5 | 17.6 | 19.5 | 21.5 | 23.4 | 25.4 | 27.3 | 29.3 | 31.2 | 33.2 | 35.1 | 37.1 | 39.0 |
7.0 | 18.9 | 21.0 | 23.1 | 25.2 | 27.3 | 29.4 | 31.5 | 33.6 | 35.7 | 37.8 | 39.9 | 42.0 |
7.5 | 20.3 | 22.5 | 24.8 | 27.0 | 29.3 | 31.5 | 33.8 | 36.0 | 38.3 | 40.5 | 42.8 | 45.0 |
8.0 | 21.6 | 24.0 | 26.4 | 28.8 | 31.2 | 33.6 | 36.0 | 38.4 | 40.8 | 43.2 | 45.6 | 48.0 |
Infusion in a bag via a controlled-infusion device
Table 2: Administration of sodium nitroprusside (100 microgram/mL) via infusion bag (rate mL/hr). Concentration = 50 mg in 500 mL = 100 microgram/mL
Dosage (microgram/kg/min) |
Weight (kg) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
45 | 50 | 55 | 60 | 65 | 70 | 75 | 80 | 85 | 90 | 95 | 100 | |
0.3 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 14 | 15 | 16 | 17 | 18 |
0.5 | 14 | 15 | 17 | 18 | 20 | 21 | 23 | 24 | 26 | 27 | 29 | 30 |
1.0 | 27 | 30 | 33 | 36 | 39 | 42 | 45 | 48 | 51 | 54 | 57 | 60 |
1.5 | 41 | 45 | 50 | 54 | 59 | 63 | 68 | 72 | 77 | 81 | 86 | 90 |
2.0 | 54 | 60 | 66 | 72 | 78 | 84 | 90 | 96 | 102 | 108 | 114 | 120 |
2.5 | 68 | 75 | 83 | 90 | 98 | 105 | 113 | 120 | 128 | 135 | 143 | 150 |
3.0 | 81 | 90 | 99 | 108 | 117 | 126 | 135 | 144 | 153 | 162 | 171 | 180 |
3.5 | 95 | 105 | 116 | 126 | 137 | 147 | 158 | 168 | 179 | 189 | 200 | 210 |
4.0 | 108 | 120 | 132 | 144 | 156 | 168 | 180 | 192 | 204 | 216 | 228 | 240 |
4.5 | 122 | 135 | 149 | 162 | 176 | 189 | 203 | 216 | 230 | 243 | 257 | 270 |
5.0 | 135 | 150 | 165 | 180 | 195 | 210 | 225 | 240 | 255 | 270 | 285 | 300 |
5.5 | 149 | 165 | 182 | 198 | 215 | 232 | 248 | 264 | 281 | 297 | 314 | 330 |
6.0 | 162 | 180 | 198 | 216 | 234 | 252 | 270 | 288 | 306 | 324 | 342 | 360 |
6.5 | 176 | 195 | 215 | 234 | 254 | 273 | 293 | 312 | 332 | 351 | 371 | 390 |
7.0 | 189 | 210 | 231 | 252 | 273 | 294 | 315 | 336 | 357 | 378 | 399 | 420 |
7.5 | 203 | 225 | 248 | 270 | 293 | 315 | 338 | 360 | 383 | 405 | 428 | 450 |
8.0 | 216 | 240 | 264 | 288 | 312 | 336 | 360 | 384 | 408 | 432 | 456 | 480 |
- Reconstitute sodium nitroprusside with 2 mL of glucose 5%
- Withdraw resulting solution and add to 500 mL bag of 5% glucose that has had 2 mL of diluent removed
- mix thoroughly
- Infusion solution has a faint orange-brownish tint. If it is highly coloured, do not use
- Sodium nitroprusside must be protected from light
- immediately wrap infusion bag and all parts of administration set with foil provided
- infusion solution is then stable for up to 24 hr from time of preparation
- Flow rate corresponding to required dosage and patient's weight in shaded area of Table 2, a more concentrated solution may be more appropriate/practical - see Table 3
Table 3: Administration of sodium nitroprusside (200 microgram/mL) via infusion bag (rate mL/hr). Concentration = 50 mg in 250 mL = 200 microgram/mL
Dosage (microgram/kg/min) |
Weight (kg) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
45 | 50 | 55 | 60 | 65 | 70 | 75 | 80 | 85 | 90 | 95 | 100 | |
0.3 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | 9 |
0.5 | 7 | 8 | 8 | 9 | 10 | 11 | 11 | 12 | 13 | 14 | 14 | 15 |
1.0 | 14 | 15 | 17 | 18 | 20 | 21 | 23 | 24 | 26 | 27 | 29 | 30 |
1.5 | 20 | 23 | 25 | 27 | 29 | 32 | 34 | 36 | 38 | 41 | 43 | 45 |
2.0 | 27 | 30 | 33 | 36 | 39 | 42 | 45 | 48 | 51 | 54 | 57 | 60 |
2.5 | 34 | 38 | 41 | 45 | 49 | 53 | 56 | 60 | 64 | 68 | 71 | 75 |
3.0 | 41 | 45 | 50 | 54 | 59 | 63 | 68 | 72 | 77 | 81 | 86 | 90 |
3.5 | 47 | 53 | 58 | 63 | 68 | 74 | 79 | 84 | 89 | 95 | 100 | 105 |
4.0 | 54 | 60 | 66 | 72 | 78 | 84 | 90 | 96 | 102 | 108 | 114 | 120 |
4.5 | 61 | 68 | 74 | 81 | 88 | 95 | 101 | 108 | 115 | 122 | 128 | 135 |
5.0 | 68 | 75 | 83 | 90 | 98 | 105 | 113 | 120 | 128 | 135 | 143 | 150 |
5.5 | 74 | 83 | 91 | 99 | 107 | 116 | 124 | 132 | 140 | 149 | 157 | 165 |
6.0 | 81 | 90 | 99 | 108 | 117 | 126 | 135 | 144 | 153 | 162 | 171 | 180 |
6.5 | 88 | 98 | 107 | 117 | 127 | 137 | 146 | 156 | 166 | 176 | 185 | 195 |
7.0 | 95 | 105 | 116 | 126 | 137 | 147 | 158 | 168 | 179 | 189 | 200 | 210 |
7.5 | 101 | 113 | 124 | 135 | 146 | 158 | 169 | 180 | 191 | 203 | 214 | 225 |
8.0 | 108 | 120 | 132 | 144 | 156 | 168 | 180 | 192 | 204 | 216 | 228 | 240 |
- Reconstitute sodium nitroprusside with 2 mL of glucose 5%
- Withdraw resulting solution and add to 250 mL bag of 5% glucose that has had 2 mL of diluent removed
- mix thoroughly
- Infusion solution has a faint orange-brownish tint. If it is highly coloured, do not use
- Sodium nitroprusside must be protected from light
- immediately wrap infusion bag and all parts of administration set with foil provided
- infusion solution is then stable for up to 24 hr from time of preparation
- Flow rate corresponding to required dosage and patient's weight in shaded area of Table 3, infusion via syringe pump may be more appropriate/practical - see Table 1
MANAGEMENT
- Aim to reduce diastolic BP to 110-115 mmHg over several hours
- Patients already taking antihypertensive drugs and the elderly will be more sensitive to sodium nitroprusside
- If BP not adequately reduced within 10 min at maximum dosage, discontinue infusion - see Accelerated hypertension guideline for alternative
Monitoring
- Monitor BP and symptoms carefully
- Over-rapid reduction in BP may produce the following symptoms:
- headache, dizziness, perspiration
- nausea, retching, abdominal pain
- palpitations, apprehension, retrosternal discomfort
- If these occur, reduce infusion rate in decrements of 0.5 microgram/kg/min
Length of treatment
- Sodium nitroprusside is metabolised to free cyanide, converted in the liver to thiocyanate
- if response obtained, continue therapy only for a few hours to avoid risk of toxicity
- If therapy required for >24 hr, consult manufacturer's literature on monitoring and management of potential toxicity, normally maximum is 3 days
- signs of toxicity include tachycardia, sweating, hyperventilation, arrhythmias, marked metabolic acidosis
Withdrawal
- Start oral antihypertensive therapy while BP is being controlled by sodium nitroprusside
- When finally withdrawing sodium nitroprusside, to prevent rebound increase in BP, reduce infusion rate gradually terminating over 15-30 min
- reduce by 25-30% every 5 min, rechecking BP before each decrement